SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)
COVID-19 vaccine development and a potential nanomaterial path forward | Nature Nanotechnology
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Nanotechnology for COVID-19: Therapeutics and Vaccine Research. - Abstract - Europe PMC
Moderna's coronavirus vaccine shows encouraging early results - The Washington Post
Moderna Therapeutics — Wikipédia
PDF) mRNA vaccines — a new era in vaccinology
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. - Abstract - Europe PMC
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery - ScienceDirect
Michael J. Hogan's research works | The Children's Hospital of Philadelphia, PA (CHOP) and other places
Crowd fund launched for 'Battlestar Galactica' actor Michael Hogan after brain injury
mRNA vaccines - a new era in vaccinology. - Abstract - Europe PMC
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Current Status of COVID‐19 (Pre)Clinical Vaccine Development - Ye - 2020 - Angewandte Chemie International Edition - Wiley Online Library
mRNA vaccines - a new era in vaccinology. - Abstract - Europe PMC
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
mRNA vaccines — a new era in vaccinology | Nature Reviews Drug Discovery
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses: Molecular Therapy
Frontiers | Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections | Immunology
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
